Cohance Lifesciences Ltd vs Shilpa Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 429.5 as of 18 May 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 years The revenue of Cohance Lifesciences Ltd for the Mar '26 is ₹ 617.28 crore as compare to the Dec '25 revenue of ₹ 550.71 crore. This represent the growth of 12.09% The revenue of Shilpa Medicare Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 410.54 crore. This represent the decline of -100% The ebitda of Cohance Lifesciences Ltd for the Mar '26 is ₹ 80.33 crore as compare to the Dec '25 ebitda of ₹ 96.65 crore. This represent the decline of -16.89% The ebitda of Shilpa Medicare Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 101.9 crore. This represent the decline of -100% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 8.31 crore over 8 quarters. This represents a CAGR of -66.80% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

FAQs for the comparison of Cohance Lifesciences Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Shilpa Medicare Ltd?

Market cap of Cohance Lifesciences Ltd is 16,431 Cr while Market cap of Shilpa Medicare Ltd is 9,329 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Shilpa Medicare Ltd?

The stock performance of Cohance Lifesciences Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Shilpa Medicare Ltd?

As of May 18, 2026, the Cohance Lifesciences Ltd stock price is INR ₹429.5. On the other hand, Shilpa Medicare Ltd stock price is INR ₹477.0.

How do dividend payouts of Cohance Lifesciences Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.